par Neijt, Jean J.P.;van der Burg, Mel E L;Guastalla, Jean Paul;George, Michael;Piccart-Gebhart, Martine
;Vermorken, Jan Baptist;Carnino, Flavio;Rotmensz, Nicole
Référence Acta oncologica, 28, 5, page (663-665)
Publication Publié, 1989
;Vermorken, Jan Baptist;Carnino, Flavio;Rotmensz, NicoleRéférence Acta oncologica, 28, 5, page (663-665)
Publication Publié, 1989
Article révisé par les pairs
| Résumé : | Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients. ©1989 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted. |



